Refine by
Dna Free Articles & Analysis
12 news found
The scientists will collect blood from the patients and will measure the number and kind of tumor cells (cellular residual disease) and DNA (molecular residual disease) released from the tumor in the blood. ...
The testing works by isolating cell-free DNA (cfDNA) from blood plasma to uncover circulating tumor DNA (ctDNA). Isolating these DNA samples from a simple blood draw is less invasive than a traditional biopsy, helping to simplify patient monitoring and more quickly guide clinical decision-making. ...
Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA). ...
Using our molecular counting technology, the assay provides absolute quantification of methylated circulating tumor DNA (ctDNA) burden. The purpose of the assay, when it becomes clinically available in Q1 2023, will be to enable clinicians to monitor patients’ responses to therapies, including in late-stage cancers for which minimal residual disease (MRD) assays may not be ...
About FoundationOne®CDx FoundationOne CDx is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using ...
He has been interested in disease diagnostics from the very beginning, and so, in addition to his work at BYTEC, he completed his doctorate with his thesis "Label-free detection of tuberculosis DNA with capacitive field-effect biosensors" at the Department of Pharmacy at Philipps University in Marburg. ...
About FoundationOne Liquid CDx FoundationOne Liquid CDx is a qualitative next generation sequencing based in vitro diagnostic test for prescription use only that uses targeted high throughput hybridization-based capture technology to analyze 324 genes utilizing circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole ...
The company leverages proprietary, state-of-the-art computational biology tools combined with targeted next generation sequencing (NGS) assay platform for highly sensitive cancer signal scoring of cell-free DNA regions linked to cancer of interest. The company is developing "Signal-X", a platform to detect multiple types of cancer; its first product, "Signal-C", ...
UNITY improves clinical specificity for cystic fibrosis carrier screening UNITY is the only prenatal screen that tests cell-free fetal DNA for cystic fibrosis, spinal muscular atrophy (SMA), sickle cell disease, and alpha and beta thalassemia using just one tube of blood from the mother. ...
A non-invasive prenatal test for Alpha Thalassemia Hb Barts and Hb Constant Spring UNITY is the only prenatal screen that tests cell-free fetal DNA for cystic fibrosis, spinal muscular atrophy (SMA), sickle cell disease, and alpha and beta thalassemia using just one tube of blood from the mother. ...
The Pilot Program is intended to increase transparency, interoperability and product identification within the medical cannabis industry. Segra will extract DNA from cannabis samples processed at its Genotyping and Molecular Lab Services Division and will provide unique DNA fingerprint codes, allowing for objective confirmation that as-supplied lots of cannabis ...
Her presentation will highlight case study data derived from Thermo Fisher's cell-free DNA assay; while Prof. Dr. José Luis Rodríguez Peralto, Ph.D., M.D., Head of the Pathology department, Hospital 12 de Octubre, Madrid, will discuss the advantages of bringing NGS into a pathology laboratory. ...